Branded

FDA approves Boehringer Ingelheim’s Spevigo

Spevigo is the first approved treatment option for generalized pustular psoriasis flares in adults.
FDA gives Incyte approval for new Pemazyre indication

Pemazyre is the first targeted treatment approved for use in the United States for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.
Axsome Therapeutics receives FDA nod for Auvelity

Auvelity is the first and only oral nmda receptor antagonist for the treatment of major depressive disorder in adults.
Arcutis launches Zoryve

Zoryve is a next-generation topical PDE4 inhibitor for adults and adolescents with plaque psoriasis.
Lilly intros citrate-free Taltz

Lilly’s citrate-free formulation of Taltz significantly reduces injection site pain, the company said.
Myovant Sciences, Pfizer gain FDA approval for new indication of Myfembree

Myfembree is a once-daily treatment for the management of moderate to severe pain associated with endometriosis.
FDA gives Daiichi Sankyo approval for Enhertu

Enhertu is the first approved therapy targeted to patients with the HER2-low breast cancer subtype, which is a newly defined subset of HER2-negative breast cancer.
Janssen receives FDA nod for new indication for Stelara

Stelara provides a new therapeutic option for children six years of age and older living with active psoriatic arthritis.

FDA gives AstraZeneca approval for Imfinzi